Figure 5.

Pharmacological specificity of cannabinoid agonist-induced suppression of paclitaxel-induced mechanical and cold allodynia. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated suppression of paclitaxel-induced mechanical allodynia was dominated by CB₁ receptor activation with some involvement of CB₂ receptors. b. The AM1710 (3.2 mg/kg/day s.c.)-induced suppression of paclitaxel-induced mechanical allodynia was blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). c. Neither AM630 (3 mg/kg/day s.c.) nor AM251 (3 mg/kg/day s.c.) reliably altered the anti-allodynic effects of WIN55,212-2 (0.5 mg/kg/day s.c.) following acetone application. d. AM630 (3 mg/kg/day s.c.), but not AM251 (3 mg/kg/day s.c.), blocked the anti-allodynic effects of AM1710 (3.2 mg/kg/day s.c.) to cold stimulation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. Taxol-Vehicle, ⁺⁺P < 0.01 vs. Taxol-Agonist, ^xxP < 0.01, ^xxxP < 0.001 Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, ^tP < 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM630 (3), and Cremophor-Vehicle, ^ϕP < 0.05, ^ϕϕP < 0.01, ^ϕϕϕP < 0.001 Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Taxol-Agonist, ^⟂P < 0.05, ^⟂⟂P < 0.01, ^⟂⟂⟂P < 0.001 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3), and Cremophor-Vehicle, ^δP < 0.05, ^δδδP <0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Taxol-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.